CLD-423 / Caldera Therapeutics, Qyuns Therap - LARVOL DELTA

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement (Businesswire) - "Upon closing, the combined company plans to operate under the name Caldera Therapeutics, Inc....In support of the proposed merger, Caldera has secured commitments for an upsized concurrent private placement expected to generate approximately $278 million in gross proceeds from a syndicate of leading healthcare institutional investors and mutual funds....The financing is expected to support the Phase 2 clinical development of CLD-423 in ulcerative colitis and Crohn’s disease, as well as potential development in additional immune-mediated diseases."

Financing • M&A • Crohn's disease • Ulcerative Colitis

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CLD-423 in Healthy Participants (ANZCTR) - P1 | N=80 | Recruiting | Sponsor: Novotech (Australia) Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2026

Enrollment open • First-in-human • Trial initiation date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease (Businesswire)

Financing • Trial status • Inflammatory Bowel Disease